Milestone Pharmaceuticals Inc (MIST)

$1.93 -0.03 (-1.53%)
Market Cap 166.93M
Revenue (ttm) 0.00
Net Income (ttm) -41.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,514,300
Avg Vol 5,984,692
Day's Range N/A - N/A
Shares Out 85.17M
Stochastic %K 8%
Beta 0.44
Analysts Strong Sell
Price Target $6.60

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collabora...

Industry: Biotechnology
Sector: Healthcare
Phone: 514 336 0444
Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 11:17 AM
Enter: $MIST Calls Strike Price: $2 Expiry Date: FEB 20 2026 Buy in Price: $0.25 - $0.50 Sell Price: $0.50 Profit : +99% (Turn every $1 into $1.99) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
TheYoungGeologist
TheYoungGeologist Jan. 14 at 3:20 AM
$MIST when do we start to learn what insurance and the payer coverage looks like? Q4 earnings call?
0 · Reply
CoinRaider
CoinRaider Jan. 14 at 1:42 AM
$MIST Says a clown who stated multiple times he was actively shorting.
1 · Reply
TomMac64
TomMac64 Jan. 14 at 12:09 AM
$MIST This guy too ZERO shares !
1 · Reply
TomMac64
TomMac64 Jan. 14 at 12:09 AM
$MIST You see this guy he has ZERO shares !
0 · Reply
TomMac64
TomMac64 Jan. 13 at 11:46 PM
$MIST Are you serious I feel like I’m trading with a bunch of newbies who are these people on this board a bunch of BOTS !?
0 · Reply
KYLE0829
KYLE0829 Jan. 13 at 11:35 PM
$MIST lots of unrealistic expectations here. Maybe just have to wait.
0 · Reply
AP1810
AP1810 Jan. 13 at 11:10 PM
$MIST These guys need sales results. Good or bad this investment is dead money until Aug 2026 (Q2 Earnings call) when they will be able to show Q2 (first full quarter of sales). Buy now if you believe in a successful launch or short more if you believe the product will be a complete flop.
0 · Reply
aak12345
aak12345 Jan. 13 at 10:08 PM
$MIST remember there are 2 sets of warrants with 31M at 1.875. I doubt that price will go much below that.
0 · Reply
TomMac64
TomMac64 Jan. 13 at 9:04 PM
$MIST Don’t get emotional it’s only a mattter of time outstanding fundamentals and yes the market is corrupt but didn’t you know that already ?
1 · Reply
Latest News on MIST
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Jan 6, 2026, 8:00 AM EST - 7 days ago

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript

Dec 15, 2025, 11:59 AM EST - 4 weeks ago

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Dec 12, 2025, 8:00 PM EST - 4 weeks ago

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 2, 2025, 5:21 PM EST - 6 weeks ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Nov 12, 2025, 7:01 AM EST - 2 months ago

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Nov 3, 2025, 8:00 AM EST - 2 months ago

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Oct 9, 2025, 8:00 AM EDT - 3 months ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Aug 19, 2025, 8:00 AM EDT - 5 months ago

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Aug 12, 2025, 7:05 AM EDT - 5 months ago

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Jul 18, 2025, 2:16 PM EDT - 6 months ago

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Jul 11, 2025, 2:37 PM EDT - 6 months ago

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Jul 11, 2025, 9:30 AM EDT - 6 months ago

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:01 AM EDT - 6 months ago

Milestone Pharmaceuticals Announces Proposed Public Offering

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Jul 11, 2025, 6:00 AM EDT - 6 months ago

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Jul 7, 2025, 10:01 AM EDT - 6 months ago

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Jun 16, 2025, 8:00 AM EDT - 7 months ago

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 8 months ago

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

May 14, 2025, 7:04 AM EDT - 8 months ago

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Stock Picks From Seeking Alpha's March 2025 New Analysts

Apr 4, 2025, 2:30 PM EDT - 10 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI ARGX CCL CEPU CF CROX CUK

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

Mar 28, 2025, 10:24 AM EDT - 10 months ago

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Mar 28, 2025, 7:06 AM EDT - 10 months ago

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 28, 2025, 7:00 AM EDT - 10 months ago

FDA Issues Complete Response Letter for Etripamil for PSVT

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Mar 21, 2025, 3:18 PM EDT - 10 months ago

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Mar 20, 2025, 8:00 AM EDT - 10 months ago

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Mar 13, 2025, 7:08 AM EDT - 10 months ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 11 months ago

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Feb 19, 2025, 8:00 AM EST - 11 months ago

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Jan 28, 2025, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Nov 12, 2024, 9:03 AM EST - 1 year ago

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Aug 8, 2024, 4:17 PM EDT - 1 year ago

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

May 31, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 29, 2024, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

May 13, 2024, 7:15 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Apr 8, 2024, 11:36 AM EDT - 1 year ago

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Mar 21, 2024, 7:14 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 4:01 PM EST - 2 years ago

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Feb 29, 2024, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Feb 28, 2024, 4:37 PM EST - 2 years ago

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

Jan 2, 2024, 7:06 AM EST - 2 years ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

CORT RPID

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Dec 26, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Nov 13, 2023, 6:57 AM EST - 2 years ago

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Nov 11, 2023, 10:00 AM EST - 2 years ago

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 11:17 AM
Enter: $MIST Calls Strike Price: $2 Expiry Date: FEB 20 2026 Buy in Price: $0.25 - $0.50 Sell Price: $0.50 Profit : +99% (Turn every $1 into $1.99) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
TheYoungGeologist
TheYoungGeologist Jan. 14 at 3:20 AM
$MIST when do we start to learn what insurance and the payer coverage looks like? Q4 earnings call?
0 · Reply
CoinRaider
CoinRaider Jan. 14 at 1:42 AM
$MIST Says a clown who stated multiple times he was actively shorting.
1 · Reply
TomMac64
TomMac64 Jan. 14 at 12:09 AM
$MIST This guy too ZERO shares !
1 · Reply
TomMac64
TomMac64 Jan. 14 at 12:09 AM
$MIST You see this guy he has ZERO shares !
0 · Reply
TomMac64
TomMac64 Jan. 13 at 11:46 PM
$MIST Are you serious I feel like I’m trading with a bunch of newbies who are these people on this board a bunch of BOTS !?
0 · Reply
KYLE0829
KYLE0829 Jan. 13 at 11:35 PM
$MIST lots of unrealistic expectations here. Maybe just have to wait.
0 · Reply
AP1810
AP1810 Jan. 13 at 11:10 PM
$MIST These guys need sales results. Good or bad this investment is dead money until Aug 2026 (Q2 Earnings call) when they will be able to show Q2 (first full quarter of sales). Buy now if you believe in a successful launch or short more if you believe the product will be a complete flop.
0 · Reply
aak12345
aak12345 Jan. 13 at 10:08 PM
$MIST remember there are 2 sets of warrants with 31M at 1.875. I doubt that price will go much below that.
0 · Reply
TomMac64
TomMac64 Jan. 13 at 9:04 PM
$MIST Don’t get emotional it’s only a mattter of time outstanding fundamentals and yes the market is corrupt but didn’t you know that already ?
1 · Reply
doledav
doledav Jan. 13 at 9:01 PM
$MIST that’s a first, I’ve never seen a stock with 85 million shares outstanding get a 75 million dollar payment and close red…..the market is such a joke
1 · Reply
doledav
doledav Jan. 13 at 8:52 PM
$MIST only 20-30 million shares bought the last couple weeks, this hedge fund probably only has seven or 800 million morel naked short shares to dump
0 · Reply
TomMac64
TomMac64 Jan. 13 at 8:35 PM
$MIST I think you should bail !
1 · Reply
Diverstj981
Diverstj981 Jan. 13 at 8:08 PM
$MIST Nice turnaround into the close. AH might get interesting.
0 · Reply
CannonPC
CannonPC Jan. 13 at 7:33 PM
$MIST I keep buying up more shares and it just keeps going down. I’m starting to wonder if I should bail soon.
2 · Reply
watchfilingdocuments
watchfilingdocuments Jan. 13 at 7:06 PM
$MIST Funds for the $75M from RTW closed today. It's non-dilutive funding: this $75 million does not dilute existing shareholders because it’s a sale of future revenue rights rather than equity or convertible debt (Initial royalty rate of about 7 percent on U.S. net sales up to $500 million). https://archive.fast-edgar.com/20260113/AABZK22C8222L2Z2222D22ZZBNITZ2T2XL82/
0 · Reply
Vincybull
Vincybull Jan. 13 at 7:02 PM
$MIST To all those who don't believe in the title because if you have shares you don't sell them and go away and look for something else.
0 · Reply
TomMac64
TomMac64 Jan. 13 at 5:59 PM
$MIST That’s not how the market works !
1 · Reply
Bcoin777
Bcoin777 Jan. 13 at 5:44 PM
$MIST this stock can easily go anywhere but up in share price it may take 2 to 3 years before company shows Any profits and by than mm's can run it to the ground
1 · Reply
doledav
doledav Jan. 13 at 4:50 PM
$MIST you could put in an at the market bid for the entire outstanding share count right now and this algo would naked short you every single share and the price wouldn’t move
0 · Reply
JeffSaves
JeffSaves Jan. 13 at 4:42 PM
$MIST Why would they have not announced the Royalty payment yet? Seems like a huge deal
2 · Reply
deweyeggbert
deweyeggbert Jan. 13 at 4:26 PM
$MIST I doubt that. Based on the information I have, they are now sitting on $1.85 cash/ps. Nothing is really priced in at its current market cap.
1 · Reply